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Introduction
Laparoscopy offers many advantages including avoid-
ance of an abdominal incision, shorter hospital stay,
and a more rapid recovery time. Large case series have
documented the safety and efficacy of laparoscopic
removal of adnexal masses. A study involving removing
suspicious adnexal masses from 138 patients reported
a mean operation time of 86 minutes (range, 25–210
minutes), a mean hospital stay of 1.5 days, and the
major intraoperative complications rate at 1.4%, which
were all favorable in comparison with those by laparo-
tomy [1]. Laparoscopy has also been shown to be fea-
sible with large adnexal masses greater than 10 cm [2].
Thus, laparoscopy is a viable option when approaching
simple or complex, and large or small adnexal masses.
However, unexpected malignancies could be in-
evitably encountered in laparoscopic adnexal surgeries.
Ovarian cancer remains the leading cause of fatality
among all gynecologic cancers. The American Cancer
Society estimates that the case number of newly diag-
nosed ovarian cancer in the United States for 2008
was 21,650 and ranked the eighth highest among can-
cers in women. However, the expected number of deaths
from ovarian cancers was 15,520 and ranked the fifth
highest, and this number is much higher than the expected
number of 7,470 of uterine corpus cancer, which was
ranked the eighth highest [3]. In the 26th Annual Report
of the Federation of International of Gynecologists
and Obstetricians (FIGO), the 5-year survival rate for
stage IA–IC ovarian cancer was 83.4–89.6% [4].
No matter whether the approach is laparotomy 
or laparoscopy, guidelines for the treatment of pa-
tients with early-stage ovarian cancer include total hys-
terectomy, bilateral salpingo-oophorectomy, bilateral
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pelvic/paraaortic lymphadenectomy, omentectomy, and
multiple intra-abdominal biopsies in stage I ovarian
cancer. Many surgeons consider laparoscopy to be a
safe and feasible approach for assessment and removal
of early ovarian cancer [5–12].
Thoughtful considerations will ensure that the pa-
tient benefits from the laparoscopic surgery while avoid-
ing the undue morbidity and without compromising
the long-term survival. Key points in ovarian cancer
treatment include the indication and feasibility of the
laparoscopic surgery for cancer, the cost and benefit
of laparoscopy in ovarian cancer for the patients and
surgeons, and the survival and recurrent outcome of
the treatment. These are discussed as follows.
Unexpected Malignancies Encountered in
Laparoscopy
The difficulties to diagnose an early adnexal cancer
preoperatively are: the vague and polymorphic pre-
sentation in its early stage, the lack of a convincible
diagnostic criteria, and the low prevalence of ovarian
cancer in the general population (about 30–50 cases
per 100,000 women) [13,14]. Few series of laparo-
scopic management of unexpected ovarian malignan-
cies have been published in the literature. In a series of
1,011 patients operated by laparoscopy, four ovarian
cancers were revealed intraoperatively in 1,209 adnexal
masses ranging from 2 cm to 25 cm in size [12], and
an Austrian survey found an incidence of 6.5 unexpected
ovarian cancer in 1,000 women with adnexal mass
managed by laparoscopy [15]. Another French survey
found 78 cases of malignant ovarian cysts out of 5,307
ovarian lesions treated by laparoscopy (1.47%), in which
18 of the 78 cases (0.34%) were ovarian cancers and
the remaining 60 were borderline tumors [16]. A recent
review concluded that the unexpected ovarian malig-
nancy was estimated to be 1% or less in premeno-
pausal patients under strict selection criteria; however,
in postmenopausal patients, this rate rises to 3.0%
[17]. Therefore, the rate of unexpected malignancies
depends mostly on the selection criteria used.
Does Rupture or Spill from the Cyst
Matter?
A concern of laparoscopic cancer surgery is cyst rup-
ture and tumor spillage during operation, which may
result in potential unfavorable sequelae and affect the
overall survival. The rate of cyst rupture in laparoscopy
has been reported as 6–27%, which is supposed to be
higher than laparotomy as a risk of tumor spillage,
although the data are not conclusive [18–21].
An earlier study indicated that a ruptured cyst was
associated with a reduced 5-year survival in stage I
epithelial ovarian cancer [22]. However, subsequent
studies have shown that intraoperative cyst rupture is
not associated with reduced survival. Some authors
showed that there was a statistically significant re-
duction in survival in the group whose cyst ruptured
before surgery compared with the group with intraop-
erative cyst rupture [23–26]. A recent retrospective
analysis of 1,545 patients with stage I disease found
that intraoperative cyst rupture had an independent
unfavorable prognostic effect on disease-free survival
(hazard ratio, 1.64; 95% confidence interval, 1.07–2.51;
p = 0.002) [27].
Feasibility of the Cancer Laparoscopy
A review of 24 patients with ovarian cancer FIGO stage
IA–B underwent laparoscopic surgery for either primary
treatment (13/24) or completion of staging (11/24)
after a mean of 12 days (range, 4–21 days) after primary
surgery reported a favorable outcome. Mean operative
time was 166 minutes (range, 118–206 minutes) for
completion of staging and 182 minutes (range, 141–246
minutes) for primary surgery. No major intraoperative
complication and no trocar metastasis occurred. Five
of the 24 patients (20.8%) received adjuvant chemo-
therapy after a median time of 7 days (mean, 5–14
days) following surgery, and two of the 24 patients
(8.3%) developed recurrence. After a median follow-
up of 46 months, disease-free survival was 91.6% and
overall survival 100% [9]. In another review of 160
patients at high or low risk for ovarian malignancy
who underwent laparoscopic removal of an adnexal
mass, the major and minor postoperative complication
rates were 2% and 4%, respectively [28].
Does Pneumoperitoneum Cause the
Acceleration of Spread of Malignant Cells?
Several studies have compared tumor growth after
laparotomy and after pneumoperitoneum in animal
models, and most of them found a greater tumor
growth after laparotomy [29–32]. Some experiments
suggested that the carbon dioxide in the pneumoperi-
toneum environment may have a growth-stimulating
effect on tumor cells [33–35].
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Port Site Metastasis
The occurrence of intraperitoneally cancerous dissemi-
nation and/or abdominal wound (port site) metas-
tases after laparoscopic procedures has been reported
by numerous authors [1,36–51]. The incidence of port
site metastasis has been reported to range from 0% to
16% in a variety of cancers, which seemed no higher
than that with laparotomy. However, port site metas-
tasis could be an isolated occurrence or as part of a
disseminated state, and the presentation of a port site
metastasis after cancer laparoscopy varies from a few
days to several years. Prognosis of patients with port
site metastasis after cancer laparoscopy varies widely
according to sites of origin and histology.
Establishment of port site metastasis needs the
presence of seeds and appropriate soil. Various possi-
ble mechanisms have been postulated as the cause 
of port site recurrence, such as advanced malignancy,
direct contamination of cancer cells following exten-
sively unprotected manipulation or presence of ascites,
gas leak around port sites in the pressure of pneu-
moperitoneum (chimney effect), and tissue acidosis in
the use of carbon dioxide. Increased traumatic injuries
at the port site or predilection of tumor cell growth in
the subcutaneous tissue may facilitate such process,
since borderline malignant tumors can harbor sole
abdominal wall implants without poor outcome. Some
procedures to minimize the risk of port site implants
have been recommended, including: (1) using wound
protectors; (2) minimizing tumor manipulation; (3)
anchoring ports to prevent dislodgment; (4) avoiding
carbon dioxide leakage and sudden desufflations; (5)
using gasless laparoscopy; (6) irrigating and suction-
ing abdomen, instruments and ports before removal;
(7) using heparin or 0.25–1% povidone-iodine solu-
tion to irrigate wounds and abdomen; (8) excising tro-
car sites and with deliberate closure of all abdominal
layers including the peritoneum after laparoscopy; or
postoperative port site radiation; (9) resuming to defin-
itive surgery or chemotherapy early; and (10) using 
5-fluorouracil, topical taurolidine or intraperitoneal
endotoxin. Despite the vast amount of literature on this
issue, solid evidence, however, is lacking on the effec-
tiveness of prevention or management [52,53].
For ovarian malignancy, the real incidence of port
site metastasis is not known, but there have been 
44 cases reported in the English language literature
[9,54,55]. In an earlier study of patients of ovarian
cancer in stage III and IV exclusively, six deaths were
noted in seven (86%) who had abdominal wall metas-
tases as compared with 63 deaths in 137 (46%) who
had no wound tumors [43]. However, the difference
did not achieve significance because of the small sam-
ple size. Another study reported that by defining the
breakpoint at 17 days, the prolonged interval of stag-
ing laparotomy after initial laparoscopic surgery was
an independent prognostic factor for the stage of dis-
ease [47]. A later series also found a significant corre-
lation between the development of port site implants
and the longer interval before the start of chemother-
apy or cytoreductive surgery; however, this study con-
cluded that the presence of port site implants (n = 9)
did not significantly impact the outcome [48]. Gener-
ally, most of the reports involved small case numbers
and limited follow-up periods; the true incidence,
mechanism, and long-term prognosis of these patients
are still unclear.
We have found in our previous study that some bio-
markers may be useful to predict the prognosis [56].
Patients who developed port site metastasis in our
series were relatively young and without stage IA tumor,
and had higher synthetic phase fraction than those
without  port site metastasis (18.2% vs. 9.9%; p = 0.003;
relative risk ratio [> 15.5% vs. ≤ 15.5%], 38.33; 95% con-
fidence interval, 3.3–449.2). Two patients were currently
alive then without disease, and their tumors were p27-
positive, and p53-, HER-2/neu- and bcl-2-negative [56].
We found that hematogenous spread could be one of
the possible mechanisms of port site metastasis, as we
noted that two patients who presented with isolated
port site recurrence developed lung recurrence at a
period after chemotherapy and a complete remission
of port site metastasis [56].
We also established a nude mouse model of lap-
aroscopy to evaluate the influence of intraperitoneal
chemotherapy with paclitaxel on the prevention of in-
traoperative cancer scattering during laparoscopy and
on the efficacy in reducing trocar site metastasis. 
We found that total tumor weights were closely corre-
lated with ascites vascular endothelial growth factor
(VEGF) concentrations in a positive exponential rela-
tionship, and paclitaxel is a drug of choice because of
not only its cytotoxic effect but also its significant anti-
VEGF ability that can block the cycle of reciprocal
stimulation of ovarian cancer growth and VEGF secre-
tion, which can result in an inhibition of both angio-
genesis and cancer cell proliferation [57]. Besides,
tumor implantation and port site metastases were
reduced more by the intraoperative intraperitoneal
administration of paclitaxel during the operation than
by administration after the operation. Thus, intra-
operative intraperitoneal administration of paclitaxel
may decrease significantly the occurrence of port site
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metastasis and intraperitoneal dissemination in an
animal study [6,58].
Conclusion
As early-stage ovarian cancer is rarely diagnosed pre-
operatively, most are encountered incidentally during
laparoscopic operation for benign adnexal mass. In the
past, laparo-conversion was recommended to ensure
an optimal staging and to avoid uncertain tumor cell
spread. However, recent advancement in technology
offers more meticulous options of minimally invasive
surgery to empower the gynecologists to manage pa-
tients of early ovarian cancer. Patients with early ovarian
cancer undergoing laparoscopic surgery could not only
achieve a same or even better surgical prognosis as com-
pared those undergoing conventional laparotomy [6,9],
but also benefit from a less traumatic surgery and a
potentially faster recovery, so that the patients could
begin with the adjuvant chemotherapy earlier, if needed.
Some disadvantages of laparoscopic surgery for
ovarian cancer could exist and should be considered
before the operation, including the difficulty to
remove large ovarian mass, inability to examine the
lymph nodes by palpation and the full extent of bowels
manually, potential risk of cancer dissemination due
to intraoperative manipulation, and possible trocar site
metastasis. However, some techniques can be applied
to any suspicious adnexal mass even without a preop-
erative diagnosis of ovarian cancer, such as excising
the whole mass without fragmentation, removing it
with cellophane bag as carefully as possible, and send-
ing for an immediate frozen section examination.
Note that intact surgical specimens and the use 
of a plastic retrieval bag do not preclude the occur-
rence of port site implants. If ovarian malignancy is
diagnosed during the operation, adequate irrigation
of povidone-iodine solution and deliberate closure of
the peritoneum and all layers of abdominal wall at port
site should be performed, whether the surgery was
converted to laparotomy for comprehensive staging 
or not. If ovarian malignancy is diagnosed days after
laparoscopy, standard cytoreductive surgery including
excision of all port sites should be performed, and 
followed by chemotherapy with or without port site
irradiation as soon as possible.
Laparoscopy has played an important role in treat-
ing early ovarian cancer. Although there are still some
problems and difficulties to overcome in treating
advanced ovarian cancers, laparoscopic management
of ovarian cancers could potentially become a trend
and an attractive surgical option in the near future.
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